The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models
The Prostate · 2025
DOI: 10.1002/pros.24879 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Haotian Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Ningbo University, Health Science Center, Ningbo University, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carbonic Anhydrase IX, Extracellular Vesicles, Biomarkers, Tumor. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by Ningbo Major Research and Development Plan Project, Ningbo Science Foundation, Basic Public Welfare Research Project of Zhejiang Pr….
Abstract (Originalsprache)
Background
Current diagnostic tools are inaccurate and not specific to prostate cancer (PCa) diagnosis. Cancer‐derived small extracellular vehicles (sEVs) play a key role in intercellular communication. In this study, we examined the diagnostic value of plasma sEV‐derived carbonic anhydrase IX (CAIX) protein for PCa and clinically significant prostate cancer (csPCa) diagnosis and avoiding unnecessary biopsies.
Methods
Plasma samples ( n = 230) were collected from the patients who underwent prostate biopsy with elevated prostate‐specific antigen (PSA) levels. sEVs were isolated and characterized, and sEV protein CAIX was measured using an enzyme‐linked immunosorbent assay. Independent predictors of csPCa (Gleason score ≥ 7) were identified, and a predictive model was established. A Nomogram for predicting csPCa was developed using data from the training cohort.
Results
The expression of sEV protein CAIX was significantly higher in both PCa and csPCa compared to benign patients and nonsignificant PCa (nsPCa) (Gleason score < 7, p < 0.001). sEV protein CAIX performed well in distinguishing PCa from benign patients. The predictive model defined by sEV protein CAIX and PSA density (PSAD) demonstrated the highest discriminative ability for csPCa (AUC = 0.895), with diagnostic sensitivity and specificity of 82.5% and 85.8%, respectively. Furthermore, sEV protein CAIX is an effective predictor of 2‐year biochemical recurrence (BCR) in PCa patients ( p = 0.013), and its high expression is significantly associated with poorer BCR‐free survival ( p < 0.05).
Conclusions
Our findings demonstrate the excellent performance of sEV protein CAIX in PCa and csPCa diagnosis. The Nomogram‐based csPCa predictive model incorporating sEV protein CAIX and PSAD exhibits strong predictive value. Additionally, assessing plasma sEV protein CAIX expression levels can further aid in evaluating patient prognosis and provide a basis for making effective treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Ningbo University, Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
- Ningbo Clinical Research Center for Urological Disease, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
- Translational Research Laboratory for Urology, Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
- Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Ningbo, Zhejiang, China.
- Cancer Care Centre, St George Hospital, Kogarah, New South Wales, Australia.
- St. George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, Kensington, New South Wales, Australia.
ORCID-Profile: Bairen Pang, Yong Li
Förderung
- This study was supported by Ningbo Major Research and Development Plan Project, Ningbo Science Foundation, Basic Public Welfare Research Project of Zhejiang Pr…
Zitieren
APA
Chen, H., Pang, B., Liu, Z., Li, B., Wang, Q., Fan, B., Han, M., Gong, J., Zhou, C., Chen, Y., Li, Y., & Jiang, J. (2025). The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models. The Prostate. https://doi.org/10.1002/pros.24879
Vancouver
Chen H, Pang B, Liu Z, Li B, Wang Q, Fan B, et al. The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models. The Prostate. 2025. doi:10.1002/pros.24879
BibTeX
@article{Chen2025,
author = {Chen, Haotian and Pang, Bairen and Liu, Zhihan and Li, Benjie and Wang, Qi and Fan, Baokun and Han, Meng and Gong, Jie and Zhou, Cheng and Chen, Yingzhi and Li, Yong and Jiang, Junhui},
title = {The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24879}
}
EUVIMED